公开(公告)号：US20170119811A1

公开(公告)日：2017-05-04

申请号：US15319014

申请日：2015-06-15

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Jacob KLEIN ,  Ronit GOLDBERG ,  Jasmine SEROR

IPC: A61K31/728 ,  A61K9/08 ,  B65D75/36 ,  A61K31/79 ,  A61K31/77 ,  B65D35/00 ,  A61K9/00 ,  A61K9/127

CPC classification number: A61K9/127 ,  A61K9/0048 ,  A61K9/08 ,  A61K31/728 ,  A61K31/77 ,  A61K31/79 ,  A61K47/10 ,  A61K47/32 ,  A61K47/36 ,  B65D35/00 ,  B65D75/36

Abstract: Formulations (e.g., solutions) comprising one or more water-soluble polymer(s), liposomes, and an aqueous carrier, are provided. The provided solutions are useful for rinsing, and/or immersing therein, a contact lens and/or in the treatment of ocular discomfort, for example, an ocular discomfort associated with a contact lens. Also provided are kits comprising the solution and a contact lens; articles-of-manufacturing comprising the solution and configured for dispending the solution; and methods utilizing the solution.

公开(公告)号：US09631175B2

公开(公告)日：2017-04-25

申请号：US14329510

申请日：2014-07-11

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Michel Revel ,  Judith Chebath ,  Michal Izrael ,  Rosalia Kaufman

IPC: A01N63/00 ,  C12N5/079 ,  C12N5/0793 ,  A61K35/30 ,  G01N33/50

CPC classification number: C12N5/0622 ,  A61K35/30 ,  C12N5/0619 ,  C12N2501/11 ,  C12N2501/115 ,  C12N2501/155 ,  C12N2501/385 ,  C12N2501/41 ,  C12N2506/02 ,  C12N2533/52 ,  C12N2533/90 ,  G01N33/5058

Abstract: A method of generating neural and glial cells is provided. The method comprising growing human stem cells under conditions which induce differentiation of said human stem cells into the neural and glial cells, said conditions comprising the presence of retinoic acid and an agent capable of down-regulating Bone Morphogenic Protein activity.

公开(公告)号：US09623049B2

公开(公告)日：2017-04-18

申请号：US13669194

申请日：2012-11-05

Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.

Inventor： Zelig Eshhar ,  Assaf Marcus ,  Tova Waks

IPC: A61K35/26 ,  A61K35/28 ,  A61K38/00 ,  A61K35/17 ,  A61K31/137 ,  A61K31/197 ,  A61K31/4245 ,  C12N5/0783 ,  A61K31/135 ,  A61K31/185 ,  A61K31/196 ,  A61K31/661 ,  A61K31/675 ,  A61K31/7076 ,  A61K39/395 ,  A61K47/48 ,  A61K48/00 ,  A61N5/10 ,  B82Y5/00 ,  A61K35/12

CPC classification number: A61K35/17 ,  A61K31/135 ,  A61K31/137 ,  A61K31/185 ,  A61K31/196 ,  A61K31/197 ,  A61K31/4245 ,  A61K31/661 ,  A61K31/675 ,  A61K31/7076 ,  A61K39/39541 ,  A61K47/6891 ,  A61K48/00 ,  A61K2035/124 ,  A61N5/10 ,  B82Y5/00 ,  C07K16/32 ,  C07K2317/24 ,  C07K2317/622 ,  C07K2317/732 ,  C12N5/0636 ,  C12N5/0638 ,  C12N2501/2302 ,  C12N2501/50 ,  C12N2501/51 ,  C12N2501/515 ,  C12N2501/59 ,  C12N2501/599 ,  C12N2510/00

Abstract: A method of treating a disease, such as cancer, by administering to a subject in need of such treatment an effective amount of allogeneic T cells with a MHC unrestricted chimeric receptor short time after partial lymphodepletion. The method also comprises administering one or more agents that delay egression of the allogeneic T cells from lymph nodes of said subject during adoptive transfer of said allogeneic T cells to the subject by trapping the T cells in the lymph nodes.

公开(公告)号：US20170032079A1

公开(公告)日：2017-02-02

申请号：US15259311

申请日：2016-09-08

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Sarel FLEISHMAN ,  Adi Goldenzweig ,  Dan S. Tawfik

IPC: G06F19/16 ,  C12N9/16 ,  G06F19/00 ,  C40B30/02 ,  G06F19/22 ,  C12N9/18 ,  C12N9/10

CPC classification number: G16B15/00 ,  C12N9/1007 ,  C12N9/16 ,  C12N9/18 ,  C12Y201/01037 ,  C12Y301/01007 ,  C12Y301/08001 ,  G16B15/20 ,  G16B30/00 ,  G16B35/00 ,  G16C20/10 ,  G16C20/60

Abstract: A method for designing and selecting a protein having a stabilized structure compared to a corresponding wild type protein, and proteins having at least six amino acid substitutions with respect to a corresponding wild type protein, designed for improved thermal stability, improved specific activity and/or improved expression levels, are provided herein.

Abstract translation: 与相应的野生型蛋白质相比，设计和选择具有稳定结构的蛋白质的方法，以及相对于相应野生型蛋白质具有至少6个氨基酸取代的蛋白质，其设计用于改善热稳定性，改善的比活性和/或 改善的表达水平。

公开(公告)号：US20170030926A1

公开(公告)日：2017-02-02

申请号：US15234364

申请日：2016-08-11

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Anthony FUTERMAN ,  Hila Zigdon

IPC: G01N33/68

CPC classification number: G01N33/6893 ,  G01N2333/705 ,  G01N2405/08 ,  G01N2800/044 ,  G01N2800/52 ,  G01N2800/56

Abstract: A biomarker of the neuronopathic types of Gaucher's disease (nGD) is provided, and use thereof for assisting the diagnosis of this form of the disease and its severity. In particular, use of the level of trans-membrane glycoprotein non-metastatic B (GPNMB) or a fragment thereof in the cerebrospinal fluid (CSF) as a diagnostic marker of nGD is provided. Further provided are methods for selecting drugs and assessing the efficacy of drugs and therapies for treating nGD.

Abstract translation: 提供了戈谢氏病（nGD）的神经元病变类型的生物标志物，并提供其用于帮助诊断这种形式的疾病及其严重性的用途。 特别地，提供了将脑脊液（CSF）中的跨膜糖蛋白非转移性B（GPNMB）或其片段的水平用作nGD的诊断标记物。 还提供了选择药物和评估药物和治疗nGD疗法的方法。

公开(公告)号：US09492100B2

公开(公告)日：2016-11-15

申请号：US14242965

申请日：2014-04-02

Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.

Inventor： Michal Neeman ,  Moriel Vandsburger

IPC: A61B5/055 ,  G01R33/56 ,  A61B5/00

CPC classification number: A61B5/055 ,  A61B5/0044 ,  A61B2576/023 ,  G01R33/5605

Abstract: The invention provides magnetic resonance imaging methods for detecting cardiac diseases including myocardial fibrosis. Specifically, the invention provides a magnetic resonance imaging (MRI) pulse sequence that could be used to perform magnetization transfer (MT) or chemical exchange saturation transfer (CEST) in the heart.

Abstract translation: 本发明提供用于检测包括心肌纤维化在内的心脏病的磁共振成像方法。 具体地，本发明提供可用于在心脏中进行磁化转移（MT）或化学交换饱和转移（CEST）的磁共振成像（MRI）脉冲序列。

公开(公告)号：US20160320384A1

公开(公告)日：2016-11-03

申请号：US15107483

申请日：2014-12-31

Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.

Inventor： Irun R. Cohen ,  Eytan Domany ,  Noam Shental ,  Ittai Fattal

IPC: G01N33/564 ,  C07K14/705 ,  A61K38/13 ,  C12Q1/68 ,  G01N33/68

CPC classification number: G01N33/564 ,  A61K38/00 ,  A61K38/13 ,  C07K14/70521 ,  C07K2319/30 ,  C12N2310/17 ,  C12Q1/6804 ,  G01N33/6854 ,  G01N2800/245 ,  G01N2800/52

Abstract: A method of assaying or monitoring the determining immunological competence of a subject, particularly for determining immunological competence in a subject, including but not limited to a transplant recipient, is provided. The method comprises measuring the levels of antibodies in a sample obtained from a subject to poly-guanine oligonucleotides.

Abstract translation: 提供了测定或监测受试者的测定免疫学能力的方法，特别是用于确定受试者的免疫学能力，包括但不限于移植受体。 该方法包括测量从受试者获得的样品中的聚鸟嘌呤寡核苷酸的抗体水平。

公开(公告)号：US20160319021A1

公开(公告)日：2016-11-03

申请号：US15212231

申请日：2016-07-16

Applicant: Yeda Research and Development Co. Ltd

Inventor： Michal Eisenbach-Schwartz ,  Kuti Baruch ,  Neta Rosenzweig

IPC: C07K16/28 ,  A61K31/4155 ,  A61K39/395

CPC classification number: C07K16/2803 ,  A61K31/404 ,  A61K31/4155 ,  A61K31/7068 ,  A61K33/36 ,  A61K38/00 ,  A61K38/005 ,  A61K38/02 ,  A61K38/14 ,  A61K38/168 ,  A61K38/18 ,  A61K38/208 ,  A61K39/395 ,  A61K39/39541 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/545 ,  A61K2039/57 ,  A61K2039/572 ,  A61K2121/00 ,  C07K16/2818 ,  C07K16/2827 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/75 ,  C07K2317/76 ,  A61K2300/00

Abstract: A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session.

Abstract translation: 一种包含活性剂的药物组合物，其引起个体中用于治疗不包括自身免疫性神经炎症性疾病，复发性多发性硬化症（RRMS）的疾病，病症，病状或损伤的个体的全身免疫抑制水平的降低 ）。 药物组合物用于通过包含至少两个治疗疗程的剂量方案给药，每个治疗过程依次包括治疗会话，随后是间隔期。

公开(公告)号：US20160311905A1

公开(公告)日：2016-10-27

申请号：US15202493

申请日：2016-07-05

Applicant: Yeda Research and Development Co. Ltd

Inventor： Michal Eisenbach-Schwartz ,  Kuti Baruch ,  Neta Rosenzweig

IPC: C07K16/28

CPC classification number: C07K16/2803 ,  A61K31/404 ,  A61K31/4155 ,  A61K31/7068 ,  A61K33/36 ,  A61K38/00 ,  A61K38/005 ,  A61K38/02 ,  A61K38/14 ,  A61K38/168 ,  A61K38/18 ,  A61K38/208 ,  A61K39/395 ,  A61K39/39541 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/545 ,  A61K2039/57 ,  A61K2039/572 ,  A61K2121/00 ,  C07K16/2818 ,  C07K16/2827 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/75 ,  C07K2317/76 ,  A61K2300/00

Abstract: A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session.

公开(公告)号：US20160310068A1

公开(公告)日：2016-10-27

申请号：US15102588

申请日：2014-12-09

Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD. ,  MOR RESEARCH APPLICATIONS LTD.

Inventor： Lior HAVIV ,  Noam SOBEL ,  Amiram CATZ ,  Itzhak GLASS ,  Anton PLOTKIN ,  Aharon WEISSBROD ,  Sagit SHUSHAN

IPC: A61B5/00 ,  A61B5/11 ,  A61B5/08 ,  A61B5/087 ,  A61N1/36 ,  A61B5/0492

CPC classification number: A61B5/4836 ,  A61B5/0488 ,  A61B5/0492 ,  A61B5/0806 ,  A61B5/0816 ,  A61B5/0823 ,  A61B5/087 ,  A61B5/1103 ,  A61B5/7282 ,  A61B5/7475 ,  A61N1/36003 ,  A61N1/3601 ,  A61N1/36014 ,  A61N1/36017 ,  G06F3/012

Abstract: A system for assisted coughing includes a first sensor for measuring a parameter which can indicate a closed glottis and producing a first signal, a processor for receiving the first signal, determining a state indicating the closed glottis and generating an instruction for a Functional Electric Stimulation (FES) controller based, at least in part, on the determining, and a FES controller for generating an electric stimulation signal.

Abstract translation: 用于辅助咳嗽的系统包括用于测量可指示闭合声门并产生第一信号的参数的第一传感器，用于接收第一信号的处理器，确定指示闭合声门的状态并产生功能性电刺激指令（ FES）控制器，至少部分地基于确定，以及用于产生电刺激信号的FES控制器。